UK approves GSK's twice-yearly asthma drug

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...
Healio

Patients with chronic spontaneous urticaria experience relief in 3 days with povorcitinib

Patients with chronic spontaneous urticaria experienced relief in itch and hives by day 3 with povorcitinib, according to ...

Mothers' Milk Might Be Key To Avoiding Childhood Food Allergies

Old Order Mennonite families typically raise their own chickens and eat a lot of eggs. That repeated exposure seems to boost ...
Pharmaceutical Commerce

Pharma Pulse: Amgen's Uplizna Secures CD19 Approval for Myasthenia Gravis, as Asthma Biologic Switches Highlight Efficacy Expectations Gap

In today’s Pharma Pulse, the FDA approves Amgen’s Uplizna (inebilizumab-cdon), the first CD19-targeted therapy for gMG with convenient twice-yearly dosing, and much more.